Oral edaravone did not significantly slow functional decline versus placebo over 48 weeks in 302 treated patients with ALS (ALSFRS-R change -12.6 vs -13.4; difference 0.78, p=0.49). It was well tolerated.
RCTn = 313
van Eijk et al. Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial